<p>帕克·韦奇曼（Parker Waichman）是一家全国性的律师事务所，目前已提起多起诉讼，原告均声称在服用诺和诺德（Novo Nordisk）的 Ozempic 或 Wegovy 后发展为 NAION。</p>
<p>, /PRNewswire/ -- 帕克·韦奇曼在新泽西州法院代表被处方 Ozempic 或 Wegovy 并发展为 NAION 的受害者提起了多起诉讼，这是一种不可逆的眼部疾病，导致一只或双眼部分或完全永久性失明。最近，在 2025 年 9 月 26 日，该事务所代表一名乔治亚州居民提起诉讼，该居民在服用 Wegovy 后发展为 NAION。<em>见 Wirth v. Novo Nordisk Inc.</em>，案号：MID-L-006890-25。</p>
<p>帕克·韦奇曼继续提起更多案件，并敦促在服用这些广泛处方的 GLP-1 受体激动剂药物后遭受严重眼部伤害的个人与他们联系以进行免费案件评估。这些药物最初是为治疗 2 型糖尿病而开发的，但因减肥而迅速流行。然而，最近的研究揭示了 semaglutide（Ozempic/Wegovy）与 NAION 之间令人不安的关联，这种疾病通过切断视神经的血流导致永久性视力丧失。服用这些药物的患者报告了突然失明、视神经损伤和其他不可逆的并发症，引发了人们对药品制造商未能警告消费者和医疗专业人员这些风险的担忧。</p>
<p>2025 年在《JAMA 眼科学》上发表的一项研究考察了九名在使用 GLP-1 药物后发展为视神经疾病的患者，其中大多数患者出现了类似 NAION 的症状。哈佛大学马萨诸塞眼耳医院的进一步研究发现，使用 semaglutide 的糖尿病患者发展 NAION 的可能性是非糖尿病患者的四倍，而非糖尿病患者因减肥而服用该药物的风险则增加了七倍。</p>
<p>尽管科学证据不断增加，但仍然存在疑问，即诺和诺德的警告是否充分反映了与这些药物相关的永久性失明的潜在风险。</p>
<p>帕克·韦奇曼律师事务所为全国受害者而战</p>
<p><em>&#34;NAION 是一种毁灭性且永久的眼部伤害诊断。来自多个知名机构的研究表明，semaglutide（Ozempic 和 Wegovy 的活性成分）与 NAION 之间存在统计学上显著的关系。尽管有这些证据，诺和诺德仍然否认现实，未能警告消费者和医疗专业人员关于这种可怕伤害的风险，必须对此负责。&#34;</em> 帕克·韦奇曼律师事务所高级诉讼顾问杰森·S·戈德斯坦（Jason S. Goldstein）表示。</p>
<p>帕克·韦奇曼律师事务所目前正在全国范围内接受因服用 Ozempic 或 Wegovy 而遭受视力丧失、失明或严重视神经损伤的个人案件。受害者可能有权获得医疗费用、失去的工资、痛苦和其他损害的赔偿。</p>
<p>受影响个人的免费案件评估</p>
<p>如果您或您的亲人使用 Ozempic 或 Wegovy 后经历了突然的视力丧失、失明或视神经损伤，您可能对药品制造商有法律索赔。帕克·韦奇曼律师事务所提供免费的、无义务的案件评估，以帮助受害者了解他们的权利并追求正义。</p>
<p>今天联系帕克·韦奇曼律师事务所</p>
<p>如需免费咨询，请拨打 1-800-YOUR-LAWYER（1-800-968-7529）或访问 YourLawyer.com 以了解更多关于您的法律选择以及如何保护您的权利。</p>
<p>关于帕克·韦奇曼律师事务所</p>
<p>帕克·韦奇曼律师事务所是一家全国知名的律师事务所，致力于为缺陷药物、危险产品、事故和企业疏忽的受害者而战。该事务所特别擅长代表因制药公司疏忽而导致眼部伤害的受害者。代表案件包括_在 Elmiron（Pentosan Polysulfate Sodium）产品责任诉讼_和_Bausch &amp; Lomb 隐形眼镜溶液产品责任诉讼_。该事务所拥有追究制药公司责任的良好记录，为受伤客户获得了数十亿的和解和判决。</p>
<p>媒体联系：</p>
<p>帕克·韦奇曼律师事务所</p>
<p>电话：1-800-YOUR-LAWYER（1-800-968-7529）</p>
<p>网站：www.yourlawyer.com</p>
<p>来源：帕克·韦奇曼律师事务所</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTI5Jk5ld3NJdGVtSWQ9Tlk4NDc5NyZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MjkxMDU2UFJfTkVXU19VU1BSX19fX19OWTg0Nzk3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTI5Jk5ld3NJdGVtSWQ9Tlk4NDc5NyZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MjkxMDU2UFJfTkVXU19VU1BSX19fX19OWTg0Nzk3"/></p>

诺和诺德公司

<p>Parker Waichman LLP 在新泽西州代表多名因服用诺和诺德的药物 Ozempic 和 Wegovy 而发展为不可逆眼病 NAION 的个人提起了多起诉讼。该律所最近为一名经历与这些药物相关的视力丧失的乔治亚州居民提起了诉讼。研究表明，semaglutide 与 NAION 之间存在显著风险，这引发了对制造商警告充分性的担忧。该律所为因这些药物导致视力丧失的受害者提供免费的案件评估</p>

<p>Parker Waichman, a national law firm, has now filed multiple lawsuits where each Plaintiff alleged that he or she developed NAION after taking Novo Nordisk's Ozempic or Wegovy.</p>
<div class="lb-trans"><p>帕克·韦奇曼（Parker Waichman）是一家全国性的律师事务所，目前已提起多起诉讼，原告均声称在服用诺和诺德（Novo Nordisk）的 Ozempic 或 Wegovy 后发展为 NAION。</p>
</div><p>, /PRNewswire/ -- Parker Waichman has now filed multiple lawsuits in New Jersey state court on behalf of victims who were prescribed Ozempic or Wegovy and developed NAION, an irreversible eye condition that causes partial or complete permanent vision loss in one or both eyes. Most recently, on September 26, 2025, the Firm filed a lawsuit on behalf of a Georgia resident who developed NAION after taking Wegovy. <em>See Wirth v. Novo Nordisk Inc.,</em> Docket No: MID-L-006890-25.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 帕克·韦奇曼在新泽西州法院代表被处方 Ozempic 或 Wegovy 并发展为 NAION 的受害者提起了多起诉讼，这是一种不可逆的眼部疾病，导致一只或双眼部分或完全永久性失明。最近，在 2025 年 9 月 26 日，该事务所代表一名乔治亚州居民提起诉讼，该居民在服用 Wegovy 后发展为 NAION。<em>见 Wirth v. Novo Nordisk Inc.</em>，案号：MID-L-006890-25。</p>
</div><p>Parker Waichman continues to file additional cases and urges individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact them for a free case review. These medications, originally developed to treat Type 2 diabetes, have surged in popularity for weight loss. However, recent studies have uncovered a disturbing link between semaglutide (Ozempic/Wegovy) and NAION, a condition that causes permanent vision loss by cutting off blood flow to the optic nerve. Patients who took these drugs have reported sudden blindness, optic nerve damage, and other irreversible complications, raising concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks.</p>
<div class="lb-trans"><p>帕克·韦奇曼继续提起更多案件，并敦促在服用这些广泛处方的 GLP-1 受体激动剂药物后遭受严重眼部伤害的个人与他们联系以进行免费案件评估。这些药物最初是为治疗 2 型糖尿病而开发的，但因减肥而迅速流行。然而，最近的研究揭示了 semaglutide（Ozempic/Wegovy）与 NAION 之间令人不安的关联，这种疾病通过切断视神经的血流导致永久性视力丧失。服用这些药物的患者报告了突然失明、视神经损伤和其他不可逆的并发症，引发了人们对药品制造商未能警告消费者和医疗专业人员这些风险的担忧。</p>
</div><p>A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from NAION-like symptoms. Additional research from Harvard's Mass Eye and Ear Institute found that diabetic users of semaglutide were four times more likely to develop NAION, while non-diabetic users taking the drug for weight loss faced a sevenfold increased risk.</p>
<div class="lb-trans"><p>2025 年在《JAMA 眼科学》上发表的一项研究考察了九名在使用 GLP-1 药物后发展为视神经疾病的患者，其中大多数患者出现了类似 NAION 的症状。哈佛大学马萨诸塞眼耳医院的进一步研究发现，使用 semaglutide 的糖尿病患者发展 NAION 的可能性是非糖尿病患者的四倍，而非糖尿病患者因减肥而服用该药物的风险则增加了七倍。</p>
</div><p>Despite growing scientific evidence, questions remain as to whether Novo Nordisk's warnings adequately reflect the potential risk of permanent blindness associated with these medications.</p>
<div class="lb-trans"><p>尽管科学证据不断增加，但仍然存在疑问，即诺和诺德的警告是否充分反映了与这些药物相关的永久性失明的潜在风险。</p>
</div><p>Parker Waichman LLP Fights for Victims Nationwide</p>
<div class="lb-trans"><p>帕克·韦奇曼律师事务所为全国受害者而战</p>
</div><p><em>&#34;NAION is a devastating, and permanent, eye injury diagnosis. Studies from multiple, reputable institutions, have shown a statistically significant relationship between semaglutide (the active ingredient in Ozempic and Wegovy) and NAION. Despite this evidence, Novo Nordisk continues to deny reality by failing to warn consumers and medical professionals about this horrific injury and must be held accountable.&#34;</em> said Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP.</p>
<div class="lb-trans"><p><em>&#34;NAION 是一种毁灭性且永久的眼部伤害诊断。来自多个知名机构的研究表明，semaglutide（Ozempic 和 Wegovy 的活性成分）与 NAION 之间存在统计学上显著的关系。尽管有这些证据，诺和诺德仍然否认现实，未能警告消费者和医疗专业人员关于这种可怕伤害的风险，必须对此负责。&#34;</em> 帕克·韦奇曼律师事务所高级诉讼顾问杰森·S·戈德斯坦（Jason S. Goldstein）表示。</p>
</div><p>Parker Waichman LLP is currently accepting cases nationwide for individuals who have suffered vision loss, blindness, or serious optic nerve damage after taking Ozempic or Wegovy. Victims may be entitled to compensation for medical expenses, lost wages, pain and suffering, and other damages.</p>
<div class="lb-trans"><p>帕克·韦奇曼律师事务所目前正在全国范围内接受因服用 Ozempic 或 Wegovy 而遭受视力丧失、失明或严重视神经损伤的个人案件。受害者可能有权获得医疗费用、失去的工资、痛苦和其他损害的赔偿。</p>
</div><p>Free Case Review for Affected Individuals</p>
<div class="lb-trans"><p>受影响个人的免费案件评估</p>
</div><p>If you or a loved one experienced sudden vision loss, blindness, or optic nerve damage after using Ozempic or Wegovy, you may have a legal claim against the drug manufacturers. Parker Waichman LLP is offering free, no-obligation case evaluations to help victims understand their rights and pursue justice.</p>
<div class="lb-trans"><p>如果您或您的亲人使用 Ozempic 或 Wegovy 后经历了突然的视力丧失、失明或视神经损伤，您可能对药品制造商有法律索赔。帕克·韦奇曼律师事务所提供免费的、无义务的案件评估，以帮助受害者了解他们的权利并追求正义。</p>
</div><p>Contact Parker Waichman LLP Today</p>
<div class="lb-trans"><p>今天联系帕克·韦奇曼律师事务所</p>
</div><p>For a free consultation, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit YourLawyer.com to learn more about your legal options and how to protect your rights.</p>
<div class="lb-trans"><p>如需免费咨询，请拨打 1-800-YOUR-LAWYER（1-800-968-7529）或访问 YourLawyer.com 以了解更多关于您的法律选择以及如何保护您的权利。</p>
</div><p>About Parker Waichman LLP</p>
<div class="lb-trans"><p>关于帕克·韦奇曼律师事务所</p>
</div><p>Parker Waichman LLP is a nationally recognized law firm dedicated to fighting for victims of defective drugs, dangerous products, accidents, and corporate negligence. Specifically, the Firm is quite experienced in representing eye injury victims due to the negligence of pharmaceutical companies. Representative cases include <em>In Re Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation</em> and <em>Bausch &amp; Lomb Contact Lens Solutions Prod. Liab. Litig.</em> With a proven track record of holding pharmaceutical companies accountable, the firm has secured billions in settlements and verdicts for injured clients.</p>
<div class="lb-trans"><p>帕克·韦奇曼律师事务所是一家全国知名的律师事务所，致力于为缺陷药物、危险产品、事故和企业疏忽的受害者而战。该事务所特别擅长代表因制药公司疏忽而导致眼部伤害的受害者。代表案件包括_在 Elmiron（Pentosan Polysulfate Sodium）产品责任诉讼_和_Bausch &amp; Lomb 隐形眼镜溶液产品责任诉讼_。该事务所拥有追究制药公司责任的良好记录，为受伤客户获得了数十亿的和解和判决。</p>
</div><p>Media Contact:</p>
<div class="lb-trans"><p>媒体联系：</p>
</div><p>Parker Waichman LLP</p>
<div class="lb-trans"><p>帕克·韦奇曼律师事务所</p>
</div><p>Phone: 1-800-YOUR-LAWYER (1-800-968-7529)</p>
<div class="lb-trans"><p>电话：1-800-YOUR-LAWYER（1-800-968-7529）</p>
</div><p>Website: www.yourlawyer.com</p>
<div class="lb-trans"><p>网站：www.yourlawyer.com</p>
</div><p>SOURCE Parker Waichman LLP</p>
<div class="lb-trans"><p>来源：帕克·韦奇曼律师事务所</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTI5Jk5ld3NJdGVtSWQ9Tlk4NDc5NyZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MjkxMDU2UFJfTkVXU19VU1BSX19fX19OWTg0Nzk3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY84797&amp;Transmission_Id=202509291056PR_NEWS_USPR_____NY84797&amp;DateId=20250929"/></p>

10:56 ET
			
			
				Parker Waichman LLP Files Lawsuit on behalf of Georgia Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Wegovy

Parker Waichman LLP 代表一名乔治亚州居民提起诉讼，声称在服用 Wegovy 后患上了不可逆的眼部疾病 NAION